Quince Therapeutics, Inc.
QNCX
$1.63
$0.021.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.71% | -100.49% | -81.07% | -90.06% | -73.63% |
| Total Depreciation and Amortization | -56.44% | -48.41% | -42.24% | 690.00% | 288.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58.55% | 242.94% | 133.67% | 145.97% | 147.97% |
| Change in Net Operating Assets | 193.48% | 647.81% | -124.48% | -5,222.50% | -749.59% |
| Cash from Operations | -28.01% | -43.66% | -74.42% | -68.60% | -40.45% |
| Capital Expenditure | -344.12% | -480.95% | -60.63% | 30.84% | 61.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 132.97% | 11,933.17% | 720.52% | 144.63% | 415.97% |
| Cash from Investing | 169.34% | 1,102.18% | 480.48% | 118.56% | 362.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Common Stock | 4,865.41% | -56.89% | 51.01% | 206.52% | 204.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,153.08% | -1,823.67% | -3,439.16% | -7,038.24% | 450.94% |
| Foreign Exchange rate Adjustments | 1,524.00% | -65.22% | 188.75% | -183.92% | -104.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 160.54% | 43.61% | 38.98% | -86.27% | 39.20% |